Monday, February 9, 2026
Pandorum Secures $18M Oversubscribed Series B for Biotech
The GMA Admin
Bengaluru biotech trailblazer Pandorum Technologies has closed an oversubscribed $18 million Series B round, fueling its audacious push into programmable regenerative medicine with dual operations spanning India and the US. Led by Protons Corporate alongside heavyweights like Galentic Pharma, Ashish Kacholia’s Noblev Advisory, Avinya Fund, and the Burman Family, the infusion—facilitated by advisor Bandana Kankani—targets clinical acceleration of its flagship exosome platform, Kuragenx, while scaling manufacturing footprints in the US and Japan. This milestone arrives hot on the heels of a $11 million pre-Series B in March 2024 and a $10 million tranche late last year, cementing Pandorum’s stature in India’s deep-tech biotech arena where global ambitions now collide with homegrown innovation.
Founders’ Vision: Rewriting Regeneration from Bengaluru to Silicon Valley
Co-founders Tuhin Das (CEO) and Vaijayanti Gupta (CSO), both MIT-trained bioengineers, launched Pandorum in 2011 to bridge biology, engineering, and computation into tunable therapies that reprogram diseased tissues—think inflammation-to-restoration or fibrosis-to-function. “Like the Ship of Theseus, the human body is in perpetual renewal; we’re restoring its biological memory,” Das remarked, framing health as a “navigational challenge in a biologically constrained information landscape.” Their exosome-based platform, Kuragenx—the “Liquid Cornea”—targets corneal blindness via a topical gel that regenerates tissue in under a year, sidestepping donor shortages that plague 12 million global patients annually.
With R&D hubs in Bengaluru and San Carlos, California, Pandorum has notched grants from India’s Department of Biotechnology, collaborations with global pharma, and proof-of-concepts in liver organoids, lung repair, and neuronal regeneration. Prior capital—$41 crore in 2020, $23 crore in 2017—propelled preclinical wins, but this Series B catapults them toward first-in-human trials, multi-tissue applications, and commercial scalability. For a nation where biotech funding hit $1.5 billion in 2025 amid 25% CAGR projections to 2030, Pandorum exemplifies the shift from generics to next-gen modalities.
Funding Breakdown: Strategic Backers Betting on Exosome Moonshots
Protons Corporate anchored the round with substantial commitment, drawing in syndicate players like Galentic Pharma (specializing in novel therapeutics) and high-profile angels including Ashish Kacholia—famed for backing unicorns like Happy McHappy—and the Burman Family of Dabur legacy. Bandana Kankani’s Nexxtmile syndicate, a repeat investor, orchestrated alignment on value milestones: clinical milestones for Kuragenx by 2027, US/Japan GMP facilities online, and pipeline expansion to chronic wounds and organ fibrosis. “Pandorum heralds India’s biotech paradigm shift—indigenous deep science rivaling global frontiers,” Kacholia noted on the pre-close buzz.
This diverse coalition signals conviction in Pandorum’s IP fortress—over 50 patents pending—and its “programmable” edge: exosomes as tunable vesicles that deliver payloads precisely, outperforming viral vectors in safety and scalability.
Pipeline Spotlight: Kuragenx Leads Charge to Clinical Reality
Kuragenx headlines as a non-surgical corneal regenerator, addressing India’s 1.2 million backlog where waitlists stretch decades. Preclinical data shows 80% haze reversal in animal models within months, with human trials eyed for late 2026. Beyond eyes, the platform tackles liver fibrosis (NASH epidemic, 25% prevalence in India), lung repair post-COVID, and neuro-regeneration for stroke—markets pegged at $50 billion combined by 2030. “From single-tissue to multi-organ repair, we’re slowing aging via rapid healing,” Das emphasized, with funds earmarked 40% for trials, 30% manufacturing, 20% team expansion (to 150 heads), and 10% computational AI for exosome design.
India’s regenerative med scene, valued at $2 billion in 2025, grows 30% YoY, but Pandorum differentiates via 3D bioprinting hybrids—corneas, skin grafts—integrated with drug discovery services for pharma clients. Global parallels like LyGenesis ($82M raised) validate the model, yet Pandorum’s cost edge (India ops at 1/3rd US costs) positions it for emerging markets dominance.
India’s Biotech inflection: From Copycat to Creator Economy
This raise underscores India’s biotech maturation: 2025 saw $4 billion inflows, up 20%, with deep-tech capturing 15% versus 5% in 2020. Government catalysts—$1 billion BioE3 policy, PLI schemes for manufacturing—align with private bets on modalities like exosomes (global TAM $10B by 2030). Challenges loom: regulatory harmonization for USFDA/PMDA, talent wars (bioengineers scarce), and clinical trial infrastructure. Yet successes like Pandorum, Eyestem, and CellX signal a cluster effect in Bengaluru-Hyderabad.
For martech pros tracking enterprise tech adjacencies, Pandorum’s story mirrors SaaS scaling: product-led innovation, global go-to-market, and AI-orchestrated R&D. Investor Amit Mangal hailed it as “India creating biotech, not just consuming,” with Kuragenx’s societal punch—eradicating corneal blindness—rivaling vaccine moonshots.
Road Ahead: Trials, Takeovers, and Tissue Revolution
With $18 million fueling Phase I/II by 2027, Pandorum eyes partnerships (Roche, Regeneron whispers) and Series C at $200 million+ valuation. “Commercialization is marathon, but impact extraordinary,” Kacholia echoed. As India’s SaaS hit $35 billion last year, biotech could mirror that trajectory—Pandorum at the vanguard.
In Delhi’s innovation corridors, this fund underscores deep science’s ROI: not just therapies, but a blueprint for global bio-leadership. Early traction—DBT grants, Bay Area pilots—positions them to heal millions while minting returns.